Abstract：
Cervical cancer is the fourth most common cancer in women worldwide and is caused by persistent infection with high-risk types of human papillomavirus (HPV). HPV viral load, the amount of HPV DNA in a sample, has been suggested to correlate with cervical disease severity, and with clinical outcome of cervical cancer. In this systematic review, we searched three databases (EMBASE, PubMed, Web of Science) to examine the current evidence on the association between HPV viral load in cervical samples and disease severity, as well as clinical outcome. After exclusion of articles not on HPV, cervical cancer, or containing clinical outcomes, 85 original studies involving 173 746 women were included. The vast majority (73/85 = 85.9%) reported that a higher viral load was correlated with higher disease severity or worse clinical outcome. Several studies reported either no correlation (3/85 = 3.5%), or the opposite correlation (9/85 = 10.6%); possible reasons being different categorization of HPV viral load levels, or the use of specific sampling methods. Despite variations in study design and populations, the above findings suggest that HPV viral load is correlated to clinical outcome, and may become an important biomarker for treatment selection and response monitoring for cervical cancer.
摘要：
宫颈癌是全球女性中第四常见的癌症，是由高危型人乳头瘤病毒（HPV）持续感染引起的。HPV病毒载量,样本中HPVDNA的含量，被认为与宫颈疾病的严重程度有关，和宫颈癌的临床结果。在这次系统审查中，我们搜索了三个数据库(EMBASE，PubMed,WebofScience）以检查宫颈样本中HPV病毒载量与疾病严重程度之间关联的当前证据，以及临床结果。排除非HPV的文章后，宫颈癌,或包含临床结果，包括85项原始研究，涉及173,746名妇女。绝大多数（73/85=85.9％）报告说，较高的病毒载量与较高的疾病严重程度或较差的临床结果相关。几项研究报告要么没有相关性(3/85=3.5%)，或相反的相关性（9/85=10.6％）;可能的原因是HPV病毒载量水平的不同分类，或使用特定的抽样方法。尽管研究设计和人群存在差异，上述结果表明，HPV病毒载量与临床结果相关，并可能成为宫颈癌治疗选择和疗效监测的重要生物标志物。
